Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun 8;5(1):46.
doi: 10.1186/s40249-016-0140-y.

Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy

Liesbeth Mieras  1 , Richard Anthony  2 , Wim van Brakel  3 , Martin W Bratschi  4 , Jacques van den Broek  5 , Emmanuelle Cambau  6 , Arielle Cavaliero  7 , Christa Kasang  8 , Geethal Perera  9 , Lee Reichman  10 , Jan Hendrik Richardus  11 , Paul Saunderson  12 , Peter Steinmann  4 , Wing Wai Yew  13
Affiliations
Review

Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy

Liesbeth Mieras et al. Infect Dis Poverty. .

Abstract

Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in the first 2-3 years after receiving SDR. In countries where SDR is currently being implemented under routine programme conditions in defined areas, questions were raised by health authorities and professional bodies about the possible risk of inducing rifampicin resistance among the M. tuberculosis strains circulating in these areas. This issue has not been addressed in scientific literature to date. To produce an authoritative consensus statement about the risk that SDR would induce rifampicin-resistant tuberculosis, a meeting was convened with tuberculosis (TB) and leprosy experts. The experts carefully reviewed and discussed the available evidence regarding the mechanisms and risk factors for the development of (multi) drug-resistance in M. tuberculosis with a view to the special situation of the use of SDR as PEP for leprosy. They concluded that SDR given to contacts of leprosy patients, in the absence of symptoms of active TB, poses a negligible risk of generating resistance in M. tuberculosis in individuals and at the population level. Thus, the benefits of SDR prophylaxis in reducing the risk of developing leprosy in contacts of new leprosy patients far outweigh the risks of generating drug resistance in M. tuberculosis.

Keywords: Leprosy; Mycobacterium tuberculosis; Post-exposure prophylaxis; Rifampicin resistance.

PubMed Disclaimer

References

    1. Bakker MI, Hatta M, Kwenang A, Van Benthem BHB, Van Beers SM, Klatser PR, et al. Prevention of leprosy using rifampicin as chemoprophylaxis. Am J Trop Med Hyg. 2005;72(4):443–448. - PubMed
    1. Moet FJ, Pahan D, Oskam L, Richardus JH, COLEP Study Group Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ. 2008;336(7647):761–764. doi: 10.1136/bmj.39500.885752.BE. - DOI - PMC - PubMed
    1. Smith CM, Smith WC. Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. MILEP2 Study Group. Mucosal Immunology of Leprosy. J Infect. 2000;41(2):137–142. doi: 10.1053/jinf.2000.0698. - DOI - PubMed
    1. Richardus RA, Alam K, Pahan D, et al. The combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster randomized controlled trial (MALTALEP study) BMC Infect Dis. 2013;13:456. doi: 10.1186/1471-2334-13-456. - DOI - PMC - PubMed
    1. WHO | Tuberculosis. http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed 17 June 2015.

MeSH terms